Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein

Vaccine

Volumn 32, Issue 51, 2014, Pages 6934-6940

  Singh, Shailbala ^a   Yang, Guojun ^a   Byrareddy, Siddappa N ^c   Barry, Michael A ^d   Sastry, K Jagannadha ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Clade C HIV 1; Mucosal adjuvants; Mucosal vaccine; NKT cell agonist; Sublingual; TLR9 agonist; Vaccine

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 9; ALPHA-GALACTOSYLCERAMIDE; CPG-OLIGONUCLEOTIDE; GALACTOSYLCERAMIDE; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, MOUSE; VIRUS ENVELOPE PROTEIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; MEMORY T LYMPHOCYTE; MONOTHERAPY; MOUSE; MUCOSAL IMMUNITY; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SALIVA ANALYSIS; T LYMPHOCYTE; VACCINATION; VIRUS IMMUNITY; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PROCEDURES; SUBLINGUAL DRUG ADMINISTRATION; VAGINA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, SUBLINGUAL; AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GALACTOSYLCERAMIDES; HIV ANTIBODIES; HIV-1; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE, INBRED BALB C; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; VACCINATION; VAGINA;

EID: 84924081042     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.051     Document Type: Article

References (49)

1. Shaw G.M., Hunter E. HIV transmission. Cold Spring Harb Perspect Med 2012, 2(11). pii: a006965. 10.1101/cshperspect.a006965.
2. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
3. Yu M., Vajdy M. Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther 2010, 10:1181-1195.
4. Strbo N., Vaccari M., Pahwa S., Kolber M.A., Doster M.N., Fisher E., et al. Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J Immunol 2013, 190:2495-2499.
5. Kaufman D.R., Barouch D.H. Translational mini-review series on vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity. Clin Exp Immunol 2009, 157:165-173.
6. Srivastava I.K., Ulmer J.B., Barnett S.W. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev Vaccines 2004, 3:S33-S52.
7. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
8. Montefiori D.C., Karnasuta C., Huang Y., Ahmed H., Gilbert P., de Souza M.S., et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012, 206:431-441.
9. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
10. Nkolola J.P., Cheung A., Perry J.R., Carter D., Reed S., Schuitemaker H., et al. Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. Vaccine 2014, 32:2109-2116.
11. Gebril A., Alsaadi M., Acevedo R., Mullen A.B., Ferro V.A. Optimizing efficacy of mucosal vaccines. Expert Rev Vaccines 2012, 11:1139-1155.
12. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012, 12:592-605.
13. Lawson L.B., Norton E.B., Clements J.D. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 2011, 23:414-420.
14. Oleszycka E., Lavelle E.C. Immunomodulatory properties of the vaccine adjuvant alum. Current Opin Immunol 2014, 28C:1-5.
15. Kool M., Fierens K., Lambrecht B.N. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 2012, 61:927-934.
16. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003, 21(Suppl. 2):S89-S95.
17. Rhee J.H., Lee S.E., Kim S.Y. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res 2012, 1:50-63.
18. Harandi A.M. Holmgren J. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr Opin Investig Drugs 2004, 5:141-145.
19. Cerundolo V., Silk J.D., Masri S.H., Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009, 9:28-38.
20. Seino K., Taniguchi M. Functional roles of NKT cell in the immune system. Front Biosci 2004, 9:2577-2587.
21. Courtney A.N., Nehete P.N., Nehete B.P., Thapa P., Zhou D., Sastry K.J. Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine 2009, 27:3335-3341.
22. Courtney A.N., Thapa P., Singh S., Wishahy A.M., Zhou D., Sastry J. Intranasal but not intravenous delivery of the adjuvant alpha-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Eur J Immunol 2011, 41:3312-3322.
23. Holmgren J., Svennerholm A.M. Vaccines against mucosal infections. Curr Opin Immunol 2012, 24:343-353.
24. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11:S45-S53.
25. Czerkinsky C., Cuburu N., Kweon M.N., Anjuere F., Holmgren J. Sublingual vaccination. Hum Vaccines 2011, 7:110-114.
26. Cuburu N., Kweon M.N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007, 25:8598-8610.
27. Kweon M.N. Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. Cytokine 2011, 54:1-5.
28. Pedersen G.K., Ebensen T., Gjeraker I.H., Svindland S., Bredholt G., Guzman C.A., et al. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS ONE 2011, 6:e26973.
29. Shim B.S., Choi Y.K., Yun C.H., Lee E.G., Jeon Y.S., Park S.M., et al. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS ONE 2011, 6:e27953.
30. Buffa V., Klein K., Fischetti L., Shattock R.J. Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice. PLoS ONE 2012, 7:e50529.
31. Siddappa N.B., Watkins J.D., Wassermann K.J., Song R., Wang W., Kramer V.G., et al. R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS ONE 2010, 5:e11689.
32. Siddappa N.B., Song R., Kramer V.G., Chenine A.L., Velu V., Ong H., et al. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol 2009, 83:1422-1432.
33. Humbert M., Rasmussen R.A., Ong H., Kaiser F.M., Hu S.L., Ruprecht R.M. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PLoS ONE 2008, 3:e3937.
34. Siddappa N.B., Hemashettar G., Wong Y.L., Lakhashe S., Rasmussen R.A., Watkins J.D., et al. Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis. J Med Primatol 2011, 40:120-128.
35. Singh S., Yang G., Schluns K.S., Anthony S.M., Sastry K.J. Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge. PLOS ONE 2014, 9:e90001.
36. Lau L.L., Jamieson B.D., Somasundaram T., Ahmed R. Cytotoxic T-cell memory without antigen. Nature 1994, 369:648-652.
37. Cerwenka A., Morgan T.M., Dutton R.W. Naive, effector, and memory CD8T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J Immunol 1999, 163:5535-5543.
38. Newman M.J. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses. Curr Opin Investig Drugs 2002, 3:374-378.
39. Ratto-Kim S., Currier J.R., Cox J.H., Excler J.L., Valencia-Micolta A., Thelian D., et al. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS ONE 2012, 7:e45840.
40. Paris R.M., Kim J.H., Robb M.L., Michael N.L. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 2010, 9:1055-1069.
41. Guillonneau C., Mintern J.D., Hubert F.X., Hurt A.C., Besra G.S., Porcelli S., et al. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 2009, 106:3330-3335.
42. Reilly E.C., Thompson E.A., Aspeslagh S., Wands J.R., Elewaut D., Brossay L. Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS ONE 2012, 7:e37991.
43. Song J.H., Kim J.I., Kwon H.J., Shim D.H., Parajuli N., Cuburu N., et al. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J Immunol 2009, 182:6851-6860.
44. Mascarell L., Lombardi V., Zimmer A., Louise A., Tourdot S., Van Overtvelt L., et al. Mapping of the lingual immune system reveals the presence of both regulatory and effector CD4+ T cells. Clin Exp Allergy 2009, 39:1910-1919.
45. Hovav A.H. Dendritic cells of the oral mucosa. Mucosal Immunol 2014, 7:27-37.
46. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
47. Qimron U., Paul L., Bar-Haim E., Bloushtain N., Eisenbach L., Staats H.F., et al. Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissues. Vaccine 2004, 22:1390-1394.
48. Forsell M.N., Schief W.R., Wyatt R.T. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS 2009, 4:380-387.
49. Lakhashe S.K., Wang W., Siddappa N.B., Hemashettar G., Polacino P., Hu S.L., et al. Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS ONE 2011, 6:e22010.